Annual Report

The report describes Evotec's 2008 acquisition of Renovis, which added pain and inflammation candidates to its pipeline; two Renovis programs entered Phase I during the year. Group revenue increased 20% to €39.6m, and the company ended 2008 with €92.4m in liquidity. The report also describes a strategic focus on advancing clinical assets and balancing research investment amid difficult market conditions.